Millipore Sigma Vibrant Logo

PC284 Anti-AML1 (Ab-1) Rabbit pAb

PC284
  
Recuperando precio...
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Maximum Quantity is
Al finalizar el pedido Más información
Ahorró ()
 
Solicitar precio
Disponibilidad a confirmar
Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

       

      Póngase en contacto con el Servicio de Atención al Cliente

      Descripción

      Replacement Information

      Tabla espec. clave

      Species ReactivityHostAntibody Type
      H, MRbPolyclonal Antibody
      Description
      Overview

      This product has been discontinued.



      Recognizes the ~58 kDa AML1 protein in HeLa, Jurkat, and NIH2T3 cells. May not detect endogenous AML1.

      Catalogue NumberPC284
      Brand Family Calbiochem®
      SynonymsAnti-Acute Myeloid Leukemia 1, Anti-Runx1
      References
      ReferencesMitani, Y., et al. 2000. FASEB J. 14, 805. Lo Coco, F., et al. 1997. Haematologica 82, 364. Mitani, K. 1997 Leukemia 11 Suppl 3, 294. Crute, B.E., et al. 1996. J. Biol. Chem. 271, 26251. Hiebert, S.W., et al. 1996. Mol. Cell Biol. 16, 1349. Kurokawa, M., et al. 1996. J. Biol. Chem. 271, 16870. Meyers, S., et al. 1996. Oncogene 13, 303. Sacchi, N., et al. 1996. Oncogene 12, 437. Meyers, S., et al. 1995. Mol. Cell Biol. 15, 1974. Miyoshi, H., et al. 1995. Nucleic Acids Res. 23, 2762. Levanon, D., et al. 1994. Genomics 23, 425.
      Product Information
      FormLiquid
      FormulationIn PBS.
      Positive controlHeLa, 3T3, or Jurkat cells
      Preservative≤0.1% sodium azide
      Applications
      Application ReferencesGel Shift Meyers, S., et al. 1996. Oncogene 13, 303. Meyers, S., et al. 1995. Mol. Cell Biol. 15, 1974.
      Key Applications Gel Shift
      Immunoblotting (Western Blotting)
      Immunoprecipitation
      Not Frozen Sections
      Not Immunofluorescence
      Not Paraffin Sections
      Application NotesFrozen Sections (not recommended) Gel Shift (see application references) Immunoblotting (5-10 μg/ml, chemiluminescence) Immunofluorescence (not recommended) Immunoprecipitation (1 μg/reaction) Paraffin Sections (not recommended)
      Application CommentsBy immunoblotting, this antibody detects AML1 in overexpressed cell lines (HeLa, 3T3); it is difficult to detect endogenous levels of AML1 in most cell lines. For gel shift assays, use Cat. No. PC284L reconstituted in 100 μl of buffer. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogena synthetic peptide corresponding to amino acids at the N-terminus of human AML1
      ImmunogenHuman
      HostRabbit
      IsotypeIgG
      Species Reactivity
      • Human
      • Mouse
      Antibody TypePolyclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage -20°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      PC284 0

      Documentation

      Anti-AML1 (Ab-1) Rabbit pAb Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Anti-AML1 (Ab-1) Rabbit pAb Certificados de análisis

      CargoNúmero de lote
      PC284

      Referencias bibliográficas

      Visión general referencias
      Mitani, Y., et al. 2000. FASEB J. 14, 805. Lo Coco, F., et al. 1997. Haematologica 82, 364. Mitani, K. 1997 Leukemia 11 Suppl 3, 294. Crute, B.E., et al. 1996. J. Biol. Chem. 271, 26251. Hiebert, S.W., et al. 1996. Mol. Cell Biol. 16, 1349. Kurokawa, M., et al. 1996. J. Biol. Chem. 271, 16870. Meyers, S., et al. 1996. Oncogene 13, 303. Sacchi, N., et al. 1996. Oncogene 12, 437. Meyers, S., et al. 1995. Mol. Cell Biol. 15, 1974. Miyoshi, H., et al. 1995. Nucleic Acids Res. 23, 2762. Levanon, D., et al. 1994. Genomics 23, 425.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision09-October-2007 RFH
      SynonymsAnti-Acute Myeloid Leukemia 1, Anti-Runx1
      ApplicationFrozen Sections (not recommended) Gel Shift (see application references) Immunoblotting (5-10 μg/ml, chemiluminescence) Immunofluorescence (not recommended) Immunoprecipitation (1 μg/reaction) Paraffin Sections (not recommended)
      DescriptionPurified rabbit polyclonal antibody. Recognizes the ~58 kDa AML1 protein.
      BackgroundThe family of nuclear transcription factors represented by AML are important transactivators of tissue-specific genes of the hematopoietic lineage and the bone cell lineage. There are currently three different mammalian proteins that are members of this family, AML1, AML2, and AML3. The AML proteins in turn form heterodimers with another protein, CBFbeta and it is this complex which has the transcription factor activity. Within the complex the AML protein provides the DNA binding function. The AML gene was discovered in 1991 by cloning the t(8;21) translocation that is common to AML. Structurally the AML protein contains a transactivation domain at the C-terminus and has homology with the Drosophila Runt gene that is the DNA binding protein of the protein. In leukemias, AML1 undergoes a translocation and becomes fused to MTG8 (ETO) and forms a chimeric protein (83 kDa). This chimera is in turn complexed with the CBFbeta gene product that also has undergone a translocation. In addition to MTG8, AML1 has also been shown to undergo translocation with TEL, and EVI. Splice variants have been reported for AML which include AML1a (30 kDa), AML1b (54 kDa), and AML1c. All forms contain the runt domain but vary in their transactivation ability. Additionally 6 major transcripts have been shown for AML due to the use of 2 promoters and differential use of 3 polyadenylation sites in addition to the splice variants.
      HostRabbit
      Immunogen speciesHuman
      Immunogena synthetic peptide corresponding to amino acids at the N-terminus of human AML1
      IsotypeIgG
      Specieshuman, mouse
      Positive controlHeLa, 3T3, or Jurkat cells
      FormLiquid
      FormulationIn PBS.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsBy immunoblotting, this antibody detects AML1 in overexpressed cell lines (HeLa, 3T3); it is difficult to detect endogenous levels of AML1 in most cell lines. For gel shift assays, use Cat. No. PC284L reconstituted in 100 μl of buffer. Antibody should be titrated for optimal results in individual systems.
      Storage Avoid freeze/thaw
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Toxicity Standard Handling
      ReferencesMitani, Y., et al. 2000. FASEB J. 14, 805. Lo Coco, F., et al. 1997. Haematologica 82, 364. Mitani, K. 1997 Leukemia 11 Suppl 3, 294. Crute, B.E., et al. 1996. J. Biol. Chem. 271, 26251. Hiebert, S.W., et al. 1996. Mol. Cell Biol. 16, 1349. Kurokawa, M., et al. 1996. J. Biol. Chem. 271, 16870. Meyers, S., et al. 1996. Oncogene 13, 303. Sacchi, N., et al. 1996. Oncogene 12, 437. Meyers, S., et al. 1995. Mol. Cell Biol. 15, 1974. Miyoshi, H., et al. 1995. Nucleic Acids Res. 23, 2762. Levanon, D., et al. 1994. Genomics 23, 425.
      Application referencesGel Shift Meyers, S., et al. 1996. Oncogene 13, 303. Meyers, S., et al. 1995. Mol. Cell Biol. 15, 1974.